アスピリン内服により卵巣がんになりにくい


方法: 1992年から2007年まで7776例の患者と11843の対照を含む、 12の卵巣がんの人口を基にした症例対照研究の統合したデータを解析。薬物使用と浸潤性上皮性卵巣がんの関連のオッズ比(ORs) をロジスティック回帰およびランダム効果のメタ解析を用いて計算。使用頻度、用量、および使用期間と卵巣がんの危険性の関連を評価。すべての統計解析は両側検定。結果:Aspirin使用は卵巣癌の危険性を減らす(OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). 非アスピリンNSAIDs使用では結果は同様であるが有意差はなく, acetaminophenでは関連がない.データの多い7つの研究では、毎日のaspirin使用者でその危険性が最も少なくなる (OR = 0.80; 95% CI = 0.67 to 0.96).用量の情報のある3つの研究では, 危険性の低下は低用量の(<100mg) aspirinで最も高く (OR = 0.66; 95% CI = 0.53 to 0.83),非アスピリンNSAIDsでは, その危険性の低下は高用量の(≥500mg) 使用で最も高い(OR = 0.76; 95% CI = 0.64 to 0.91).
J Natl Cancer Inst. 2014 Feb 1;106(2):djt431. doi: 10.1093/jnci/djt431.
Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium.
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, the Australian Cancer Study (Ovarian Cancer), Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N; Ovarian Cancer Association Consortium.
•Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (BT, LAB, NW); University of Texas School of Public Health, Houston, TX (RBN); Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (WL); Channing Division of Network Medicine (MAM, EMP) and Obstetrics and Gynecology Epidemiology Center (DWC, KLT), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard School of Public Health, Boston, MA (MAM, EMP, DWC, KLT); Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN (ELG); Queensland Institute of Medical Research, Brisbane, Australia (PMW, CMN, SJJ, Australian Ovarian Cancer Study Group, the Australian Cancer Study (Ovarian Cancer); Peter MacCallum Cancer Centre, East Melbourne, Australia (Australian Ovarian Cancer Study Group); Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT (HAR); Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA (MAR, JAD); Department of Community and Family Medicine, Section of Biostatistics & Epidemiology, Dartmouth Medical School, Lebanon, NH (JAD); Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (MTG); Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI (GL); Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (SKK, EH, AJ); Gynaecologic Clinic, Copenhagen University Hospital, Copenhagen, Denmark (SKK); The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ (EVB, MGK, UC); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY (SO); Department of Epidemiology, School of Medicine, University of California Irvine, Irvine, CA (HA, AZ); Department of Women's Cancer, University College London, EGA Institute for Wo
[PR]

by fibromyalgia11 | 2014-02-09 12:29 | アセトアミノフェン、NSAID
line

世界標準の線維筋痛症を専門家が説明します


by fibromyalgia11
line